Search

Takeda Pharmaceutical Co Ltd ADR

Suletud

SektorTervishoid

17.41 -0.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.34

Max

17.48

Põhinäitajad

By Trading Economics

Sissetulek

138B

113B

Müük

105B

1.2T

P/E

Sektori keskmine

42.622

57.002

Aktsiakasum

0.48

Dividenditootlus

3.53

Kasumimarginaal

9.279

Töötajad

47,029

EBITDA

180B

337B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+20.14% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

3.53%

2.22%

Turustatistika

By TradingEconomics

Turukapital

351M

56B

Eelmine avamishind

17.81

Eelmine sulgemishind

17.41

Uudiste sentiment

By Acuity

100%

0%

323 / 340 Pingereas Healthcare

Takeda Pharmaceutical Co Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. aug 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12. aug 2026, 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12. aug 2026, 23:51 UTC

News

Fossil Group Inc reported second-quarter sales of $209.7 million, exceeding expectations. Shares are trading sharply higher in after-market hours.

12. aug 2026, 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

12. aug 2026, 23:51 UTC

Social Media
News

Harmonic Inc. reported strong Q2 results, with adjusted EPS of $0.24 and raised full-year guidance, leading shares higher in after-market hours.

12. aug 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

12. aug 2026, 23:46 UTC

News

Cummins shares are higher in after-market trading following strong Q2 earnings of $9.46 billion, surpassing analyst expectations despite an adjusted EPS miss.

12. aug 2026, 23:46 UTC

News

Wendy's shares declined in after-market hours after earlier gains on news of a potential buyout bid from Nelson Peltz's Trian Fund Management.

12. aug 2026, 23:41 UTC

News

Granite Construction secures a $31 million contract for the Willow Rock Energy Storage Center, boosting its project portfolio. Shares are higher in after-market trading.

12. aug 2026, 23:41 UTC

News

Mistras Group raised its fiscal year revenue guidance to $740-$755 million, driving shares higher in after-market trading. Adjusted EBITDA is expected around $93.5 million.

12. aug 2026, 23:41 UTC

News
Social Media

Jack in the Box Inc. reports third-quarter earnings with EPS of $1.08, exceeding expectations. The stock is trading higher in after-market hours.

12. aug 2026, 23:41 UTC

Social Media
News

EnerSys reported strong first-quarter results, with adjusted EPS of $3.66 and revenue of $935.6 million. Shares are higher in after-market trading.

12. aug 2026, 23:41 UTC

News
Social Media

Coherent Corp shares fell in after-hours trading despite strong fourth-quarter results, including adjusted EPS of $1.74 and revenue of $2.05 billion.

12. aug 2026, 23:41 UTC

Social Media
News

Enovix Corp shares are lower in after-market hours following mixed second-quarter results and lower-than-expected third-quarter revenue guidance.

12. aug 2026, 23:36 UTC

Social Media
News

Cheniere Energy raised its 2026 earnings and production guidance despite a quarterly loss. Shares are higher in after-market trading amid rising natural gas prices.

12. aug 2026, 23:36 UTC

News

Alexandria Real Estate Equities has priced a $1 billion offering of 7.250% junior subordinated notes, with shares modestly higher in after-market trading.

12. aug 2026, 23:36 UTC

News

Nasdaq Inc. shares gained in after-market trading, reaching a monthly high as inflation data eased concerns over Federal Reserve rate hikes.

12. aug 2026, 23:26 UTC

News

Red Robin Gourmet Burgers shares rose in after-market trading following a Q2 earnings report that showed adjusted earnings and revenue exceeding analyst expectations.

12. aug 2026, 23:26 UTC

News

Trian Fund Management increased its stake in GE Healthcare Technologies to 3.1 million shares, contributing to a modest rise in after-market hours.

12. aug 2026, 23:26 UTC

News
Correlated Moves

Vishay Intertechnology announced a quarterly dividend of $0.10 per share, enhancing investor sentiment as shares trade higher in after-market hours.

12. aug 2026, 23:21 UTC

News

Duke Energy has restored power to over 171,000 customers in Greater Cincinnati. Shares are gaining in after-market hours amid this progress.

12. aug 2026, 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

12. aug 2026, 23:11 UTC

News

Goldman Sachs will acquire NEOS Investments for up to $2.25 billion, enhancing its asset management division with new income ETFs. Shares are higher in after-market trading.

12. aug 2026, 23:06 UTC

News

Spero Therapeutics reports FDA approval of Utebzi and secures $105 million financing. Shares are trading higher in after-market hours.

12. aug 2026, 23:06 UTC

News
Social Media

Meta Platforms faces a federal trial over youth safety violations. In after-market trading, shares are slightly higher despite ongoing legal challenges.

12. aug 2026, 23:06 UTC

News

Phillips 66 shares rose in after-market trading following a strong second-quarter performance and a $10 billion increase in buyback authorization.

12. aug 2026, 23:06 UTC

News

FormFactor Inc will participate in key investor conferences, boosting market interest. Shares are higher in after-market trading following the announcement.

12. aug 2026, 23:06 UTC

Social Media
News

NextEra Energy has secured a $3.3 billion investment for natural gas projects in Texas and Pennsylvania, though shares are trading lower in after-market hours.

12. aug 2026, 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

12. aug 2026, 23:01 UTC

News

Kimball Electronics shares are lower in after-market trading following a quarterly adjusted EPS loss of $0.01, missing expectations of $0.39.

Võrdlus sarnastega

Hinnamuutus

Takeda Pharmaceutical Co Ltd ADR Prognoos

Hinnasiht

By TipRanks

20.14% tõus

12 kuu keskmine prognoos

Keskmine 21 USD  20.14%

Kõrge 21 USD

Madal 21 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Takeda Pharmaceutical Co Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat